PROCEPT BioRobotics Corporation (PRCT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in ...

PROCEPT BioRobotics Corporation (PRCT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...

SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing ...

In the assessment of 12-month price targets, analysts unveil insights for PROCEPT BioRobotics, presenting an average target of $100.5, a high estimate of $112.00, and a low estimate of $90.00. A 4 ...

Analysts have set 12-month price targets for PROCEPT BioRobotics, revealing an average target of $79.0, a high estimate of $94.00, and a low estimate of $69.00.

Dice Therapeutics raised $204 million from its IPO to support development of oral drugs that could compete against biologic drugs that are injected or infused. Also debuting on the public markets ...

PROCEPT BioRobotics has raised $118 million in an equity financing. Funds will support the worldwide launch of its Aquablation therapy for BPH.